CN114042045A - 一种采用等量递加法的制粒方法 - Google Patents
一种采用等量递加法的制粒方法 Download PDFInfo
- Publication number
- CN114042045A CN114042045A CN202111484257.5A CN202111484257A CN114042045A CN 114042045 A CN114042045 A CN 114042045A CN 202111484257 A CN202111484257 A CN 202111484257A CN 114042045 A CN114042045 A CN 114042045A
- Authority
- CN
- China
- Prior art keywords
- granulation
- mixed powder
- process according
- powder
- caffeine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000000750 progressive effect Effects 0.000 title description 5
- 238000005469 granulation Methods 0.000 claims abstract description 11
- 230000003179 granulation Effects 0.000 claims abstract description 11
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 18
- 239000011812 mixed powder Substances 0.000 claims description 11
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 9
- 229960001948 caffeine Drugs 0.000 claims description 9
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 206010004542 Bezoar Diseases 0.000 claims description 2
- 229960001280 amantadine hydrochloride Drugs 0.000 claims description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 230000007306 turnover Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物制粒技术领域，尤其涉及一种采用等量递加法的制粒方法，由于本发明使用了等量递加法来制备药剂，因此当量小药物研细后，加入等体积其他细粉混匀，如此倍量增加混合至全部混匀，再过筛混合即可，使组分充分混合并均匀，已解决组分比例相差悬殊的情况下获得准确的物料配比。
Description
技术领域
本发明涉及药物制粒技术领域，尤其涉及一种采用等量递加法的制粒方法。
背景技术
现有技术中，在制剂的时候,当组分比例相差悬殊的情况下使用传统的配制方法会导致无法获得准确的配比，导致成品质量较差。
发明内容
本发明所要解决的问题是在组分比例相差悬殊的情况下如何获得准确的物料配比的问题。
为解决上述技术问题，本发明提供了一种采用等量递加法的制粒方法，步骤如下：
S1、取人工牛黄1.08kg、咖啡因1.6021kg、马来酸氯苯那敏0.2268kg，分别过筛，从而分别得到上述物料的细粉和粗渣；
S2、将咖啡因、马来酸氯苯那敏的粗渣分别进行研磨，然后再次过目筛，直至完全过筛；
S3、取蔗糖粉3.0kg平铺于不锈钢槽中，将完全过筛后的咖啡因、马来酸氯苯那敏以及人工牛黄置入不锈钢槽中，进行预混操作，从而获得1#混粉；
S4、取对乙酰氨基酚27.0kg，盐酸金刚烷胺10.81kg、蔗糖粉69.0kg以及1#混粉，按顺序依次加入到混合机中，上述物料混合时间为50min，混合结束后收集最终混粉112.7089kg；
S5、将上述最终混粉平均分成14份，每份8.05kg，分别装于周转桶(袋)中，备用。
由于本发明使用了等量递加法来制备药剂，因此当量小药物研细后，加入等体积其他细粉混匀，如此倍量增加混合至全部混匀，再过筛混合即可，使组分充分混合并均匀，已解决组分比例相差悬殊的情况下获得准确的物料配比。
具体实施方式
本发明涉及一种采用等量递加法的制粒方法，具体实施例如下：
实施方案一:按照配料操作步骤等量递加，检测混合粉咖啡因和马来酸氯苯那敏含量均匀度值，如下表数据：
实施方案二:按照配料操作步骤等量递加，检测混合粉咖啡因和马来酸氯苯那敏含量均匀度值，如下表数据：
实施方案三:按照配料操作步骤等量递加，检测混合粉咖啡因和马来酸氯苯那敏含量均匀度值，如下表数据：
可以理解，本发明是通过一些实施例进行描述的，本领域技术人员知悉的，在不脱离本发明的精神和范围的情况下，可以对这些特征和实施例进行各种改变或等效替换。另外，在本发明的教导下，可以对这些特征和实施例进行修改以适应具体的情况及材料而不会脱离本发明的精神和范围。因此，本发明不受此处公开的具体实施例的限制，所有落入本申请的权利要求范围内的实施例都属于本发明所保护的范围内。
Claims (5)
1.一种采用等量递加法的制粒方法，其特征在于：步骤如下：
S1、取人工牛黄1.08kg、咖啡因1.6021kg、马来酸氯苯那敏0.2268kg，分别过筛，从而分别得到上述物料的细粉和粗渣；
S2、将咖啡因、马来酸氯苯那敏的粗渣分别进行研磨，然后再次过目筛，直至完全过筛；
S3、取蔗糖粉3.0kg平铺于不锈钢槽中，将完全过筛后的咖啡因、马来酸氯苯那敏以及人工牛黄置入不锈钢槽中，进行预混操作，从而获得1#混粉；
S4、取对乙酰氨基酚27.0kg，盐酸金刚烷胺10.81kg、蔗糖粉69.0kg以及1#混粉，按顺序依次加入到混合机中，上述物料混合时间为50min，混合结束后收集最终混粉112.7089kg；
S5、将上述最终混粉平均分成14份，每份8.05kg，分别装于周转桶(袋)中，备用。
2.根据权利要求1所述的一种采用等量递加法的制粒方法，其特征在于：所述过筛的筛目为100目。
3.根据权利要求1所述的一种采用等量递加法的制粒方法，其特征在于：所述混合机为三维运动混合机。
4.根据权利要求1所述的一种采用等量递加法的制粒方法，其特征在于：所述S4步骤的损耗为0.028kg。
5.根据权利要求1所述的一种采用等量递加法的制粒方法，其特征在于：所述S5步骤的损耗为0.0089kg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111484257.5A CN114042045A (zh) | 2021-12-07 | 2021-12-07 | 一种采用等量递加法的制粒方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111484257.5A CN114042045A (zh) | 2021-12-07 | 2021-12-07 | 一种采用等量递加法的制粒方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114042045A true CN114042045A (zh) | 2022-02-15 |
Family
ID=80212452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111484257.5A Pending CN114042045A (zh) | 2021-12-07 | 2021-12-07 | 一种采用等量递加法的制粒方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114042045A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104415054A (zh) * | 2013-08-20 | 2015-03-18 | 哈药集团三精制药股份有限公司 | 一种速释复方氨酚烷胺片的制备方法 |
| CN109846905A (zh) * | 2019-04-17 | 2019-06-07 | 葵花药业集团北京药物研究院有限公司 | 一种小儿氨酚烷胺颗粒的制备方法 |
-
2021
- 2021-12-07 CN CN202111484257.5A patent/CN114042045A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104415054A (zh) * | 2013-08-20 | 2015-03-18 | 哈药集团三精制药股份有限公司 | 一种速释复方氨酚烷胺片的制备方法 |
| CN109846905A (zh) * | 2019-04-17 | 2019-06-07 | 葵花药业集团北京药物研究院有限公司 | 一种小儿氨酚烷胺颗粒的制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 李瑞等: "《药剂学实验》", 华中科技大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3353949A (en) | Method for preventing the segregation of mixed fertilizer | |
| DE4428692C2 (de) | Trockengemenge zur Herstellung einer Zementsuspension sowie Verfahren zu seiner Herstellung und Vorrichtung zur Durchführung des Verfahrens | |
| DE2412117A1 (de) | Verfahren zur herstellung von granulaten | |
| CN114042045A (zh) | 一种采用等量递加法的制粒方法 | |
| CN104586806B (zh) | 一种左乙拉西坦缓释片及其制备方法 | |
| JP2021518857A (ja) | 無添加漢方薬の細胞壁破壊粉末の顆粒製剤の製造方法 | |
| CN102450341A (zh) | 使用豆腐的微粉化溶液制备豆腐的方法 | |
| CN112321232B (zh) | 一种防渗墙用塑性混凝土及其制备方法及其施工工艺 | |
| CN104784147B (zh) | 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法 | |
| CN103110597B (zh) | 盐酸厄洛替尼片及其制备方法 | |
| CN106806132A (zh) | 一种适于粘性物料的制粒方法 | |
| CN108358481B (zh) | 一种风化细砂岩基水泥及其制备方法 | |
| DE4013871C2 (de) | Verfahren zur Herstellung einer Zementsuspension für eine Verpressung von Rissen in Steinmaterial | |
| CN113038938A (zh) | 呋喹替尼的药物制剂及其应用 | |
| CN106913556B (zh) | 一种利福喷丁胶囊及其制备方法 | |
| CN104706624A (zh) | 一种以含中药的植物油为增塑剂的载药压敏胶贴剂及其制备方法 | |
| EP0299482B1 (de) | Verfahren zur Herstellung von Granulaten oder Formkörpern aus staubförmigen mineralischen Stoffen | |
| CN112022817B (zh) | 一种硝苯地平片剂组合物及其制备方法 | |
| JP2004024255A (ja) | イネ栽培における倒伏軽減方法 | |
| CN112791057A (zh) | 一种含依度沙班的缓释制剂及制备方法 | |
| CN106822012A (zh) | 一种盐酸贝那普利片及其制备方法 | |
| CN105130716A (zh) | 机械混合制备602微烟药的方法 | |
| DE60313374T2 (de) | Verfahren zur minimierung von verlusten durch adhäsion an geräteoberflächen | |
| DE3103338A1 (de) | "verfahren zur herstellung von schnell loeslichem kleister auf basis von celluloseethern und deren verwendung als tapetenkleister" | |
| CN108272761A (zh) | 复方对乙酰氨基酚片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220215 |
|
| RJ01 | Rejection of invention patent application after publication |